Journal of Cancer Research and Therapeutics

BRIEF COMMUNICATIONS
Year
: 2006  |  Volume : 2  |  Issue : 3  |  Page : 144--146

Trastuzumab: Is the new evidence revolutionary?


Anusheel Munshi, Pritanjali Singh, Rakesh Jalali 
 Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India

Correspondence Address:
Anusheel Munshi
Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai
India

A few years back, the survival benefit of trastuzumab in HER 2 positive breast cancer patients presenting with metastatic disease was proven in a randomized setting. Recently a number of randomized trials have reported their results in the adjuvant setting in HER 2 positive patients. These trials have been considered by some as a landmark in the evolution of breast cancer management. Although the data is encouraging, it need to be seen in a proper perspective keeping in mind the limitations and the side effects reported. This article stresses the use of Herceptin in carcinoma breast patients in adjuvant setting with a cautionary eye.


How to cite this article:
Munshi A, Singh P, Jalali R. Trastuzumab: Is the new evidence revolutionary?.J Can Res Ther 2006;2:144-146


How to cite this URL:
Munshi A, Singh P, Jalali R. Trastuzumab: Is the new evidence revolutionary?. J Can Res Ther [serial online] 2006 [cited 2021 Apr 15 ];2:144-146
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2006;volume=2;issue=3;spage=144;epage=146;aulast=Munshi;type=0